Jiashitang released its 2026 semi-annual report. First-half net profit attributable to the parent company was 86.76 million yuan, down 19.1% year-on-year. Operating revenue was 8.28 billion yuan, down 14.7% year-on-year. Net profit attributable to the parent after deducting non-recurring items was 77.98 million yuan, down 19.0% year-on-year. Net operating cash flow was 437 million yuan, down 3.5% year-on-year. Earnings per share were 0.2974 yuan. In the second quarter, operating revenue was 4.31 billion yuan, down 14.2% year-on-year, and net profit attributable to the parent was 48.68 million yuan, down 20.4% year-on-year. As of the end of the second quarter, total assets were 11.616 billion yuan, down 8.9% from the end of the previous year, and net assets attributable to the parent were 4.439 billion yuan, up 2.0% from the end of the previous year. The company is mainly engaged in pharmaceutical distribution, covering drug wholesale, medical device wholesale, chain retail, and pharmaceutical logistics. During the reporting period, in drug sales, as one of the main distributors of essential medicines in Beijing, the company worked to consolidate its core existing market while expanding into incremental markets. The medical device business faced difficulties due to policy impacts, and the company is actively planning a transformation. The dual-channel and DTP businesses in the chain retail segment grew strongly. The logistics segment undertook the task of stockpiling public health emergency supplies.
Cachet Pharmaceutical Co LtdFirst-half net profit fell 19.1% year-on-year, with revenue down 14.7%.
